Platelet factor-4 (CXCL4/PF-4): An angiostatic chemokine for cancer therapy |
| |
Authors: | Zhe Wang He Huang |
| |
Affiliation: | Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 30072, China; Key Laboratory of System Bioengineering, Ministry of Education, Tianjin University, Tianjin 300072, China |
| |
Abstract: | Platelet factor-4 (CXCL4/PF-4) is the first chemokine identified to have several biological functions. Notably, CXCL4/PF-4 inhibits endothelial cell proliferation and migration, leading to suppression of angiogenesis. Since angiogenesis is essential for the growth of most primary tumors and their subsequent metastases, it is a target for cancer therapy; due to its multiple functions, CXCL4/PF-4 is a potential clinical anti-tumor agent. This report reviews the mechanisms of CXCL4/PF-4 angiostatic activity, including interference with angiogenic growth factors bFGF-2 and VEGF165, activation of CXCR3B, interactions with integrins, interference with cell cycle, interactions with factors such as VEGF121 and CXCL8/IL-8, and derived molecules of CXCL4/PF-4 with angiostatic and anti-tumoral activities in different models in vivo or in vitro. |
| |
Keywords: | Platelet factor-4 Angiogenesis Cancer therapy |
本文献已被 ScienceDirect 等数据库收录! |
|